{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-26-000056","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2026-06-30T11:00:24+00:00","discovered_at":"2026-06-30T11:05:00.309624+00:00","generated_at":"2026-06-30T11:05:11.097578+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Novocure's Optune Pax receives CE Mark for locally advanced pancreatic cancer","bullets":["CE Mark supported by Phase 3 PANOVA-3 trial showing statistically significant mOS improvement.","mOS 16.2 vs 14.2 months (HR 0.82, p=0.039) in ITT; 18.3 vs 15.1 months in mITT.","Time to pain progression extended 6.1 months (15.2 vs 9.1 months, HR 0.74, p=0.027).","Optune Pax already FDA-approved Feb 2026; launch in Germany planned in coming weeks.","Device well-tolerated; most AEs mild-moderate skin events; no new safety signals."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-26-000056","json":"https://secwatch.observer/filing/0001645113-26-000056.json","markdown":"https://secwatch.observer/filing/0001645113-26-000056.md","text":"https://secwatch.observer/filing/0001645113-26-000056.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000056/0001645113-26-000056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000056/nvcr-20260630.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T11:05:11.097578+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}